187266-46-2

Upstream product

• 75-77-4 chloro-trimethyl-silane 
• 187266-45-1 (3R,5S)-3,5-Bis-benzyloxy-cyclohexanone 
• 50409-12-6 cis,cis-1,3,5-trihydroxycyclohexane 
• 2041-15-8 1,3,5-cyclohexanetriol 
• 100-39-0 benzyl bromide 
• 187266-44-0 (1R,3S,5R)-3,5-Bis-benzyloxy-cyclohexanol 
• 187266-42-8 all-cis-5-(tert-butyldimethyl-silanyloxy)-cyclohexane-1,3-diol 
• 187266-43-9 ((1S,3R,5S)-3,5-Bis-benzyloxy-cyclohexyloxy)-tert-butyl-dimethyl-silane 

Downstream Products

• 187266-51-9 (E)-(3R,5S)-3,5-Bis-benzyloxy-7-phenyl-hept-6-enoic acid methyl ester 
• 187266-50-8 (3R,5S)-3,5-Bis-benzyloxy-6-oxo-hexanoic acid methyl ester 
• 187266-48-4 (3R,5S)-3,5-Bis-benzyloxy-6-hydroxy-hexanoic acid 
• 187266-49-5 (3R,5S)-3,5-Bis-benzyloxy-6-hydroxy-hexanoic acid methyl ester 

Relevant academic research and scientific papers

Enantioselective synthesis of the lactone moiety of HMG-CoA reductase inhibitor: Stereoselective synthesis of (+)-(4R,6R)-4-hydroxy-6-(2-phenylethyl)-tetrahydro-2H-pyran-2-one

The enantioselective synthesis of the lactone moiety of (+)-compactin and (+)-mevinolin was established starting from a meso-3,5-dihydroxycyclohexanone derivative by employing an enantioselective deprotonation strategy.